Mandate

Vinge has advised SBB in connection with the distribution of the shares in Neobo Fastigheter

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (publ) (”SBB”) in connection with the distribution of the shares in Neobo Fastigheter AB (publ) (”Neobo”) to the A and B shareholders in SBB. The resolution on the distribution was adopted at the Extraordinary General Meeting of SBB on 21 December 2022 and the distribution was carried out on 30 December 2022.

Neobo is a Swedish property company with its head office in Stockholm that long-term manages and refines rental properties in several locations in Sweden. The property portfolio is diversified over 40 municipalities with a total property value of SEK 15.8 billion. Residential properties account for 97 percent of the property portfolio’s market value and the remaining market value is made up of other properties.

Vinge’s team consisted of Jesper Schönbeck, Rikard Lindahl, Joel Magnusson, Johannes Akyol, Gabriel Chabo, Clara Sohlberg, Kristoffer Larson, Albert Wållgren, Kamyar Najmi, Victor Ericsson and Maria Schultzberg.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025